The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients.

IF 0.8 4区医学 Q3 MEDICINE, GENERAL & INTERNAL Journal of the Pakistan Medical Association Pub Date : 2024-10-01 DOI:10.47391/JPMA-BAGH-16-25

Abdul Hameed Alqaseer, Alaa Kareem Dhayef, Ammar Waham Ashor

{"title":"The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients.","authors":"Abdul Hameed Alqaseer, Alaa Kareem Dhayef, Ammar Waham Ashor","doi":"10.47391/JPMA-BAGH-16-25","DOIUrl":null,"url":null,"abstract":"Objective: To determine whether tocilizumab improved outcomes of patients hospitalised with severe coronavirus disease-2019 cytokine storm syndrome.Methods: The case-control study was conducted at Al-Yarmouk Teaching Hospital, Baghdad, and Al Shatra General Hospital, Thi Qar, Iraq, from September 2020 to March 2021, and comprised patients with severe acquired respiratory syndrome-corona virus-2 pneumonia who were not candidates for mechanical ventilation and received a single-dose intravenous infusion of tocilizumab 8mg/kg in group A. The outcomes were compared with patients in group B who received only standard care. Data was analysed using SPSS 26.Results: Of the 60 patients, 30(50%) were in group A; 22(73.3%) males and 8(26.7%) females with mean age 56.63±10.92 years. There were 30(50%) patients in control group B; 24(80%) males and 6(20%) females with mean age 54.8±6.18 (p>0.05). Group A showed significant changes compared to group B in the levels of interleukin-6, serum ferritin, D-dimer, procalcitonin, lymphocytes count and oxygen saturation (p<0.05). Mortality rate was not significantly different between the groups (p>0.05).Conclusions: Majority of the acute phase inflammatory markers were reduced significantly by treatment with tocilizumab.","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"74 10 (Supple-8)","pages":"S111-S118"},"PeriodicalIF":0.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA-BAGH-16-25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine whether tocilizumab improved outcomes of patients hospitalised with severe coronavirus disease-2019 cytokine storm syndrome.

Methods: The case-control study was conducted at Al-Yarmouk Teaching Hospital, Baghdad, and Al Shatra General Hospital, Thi Qar, Iraq, from September 2020 to March 2021, and comprised patients with severe acquired respiratory syndrome-corona virus-2 pneumonia who were not candidates for mechanical ventilation and received a single-dose intravenous infusion of tocilizumab 8mg/kg in group A. The outcomes were compared with patients in group B who received only standard care. Data was analysed using SPSS 26.

Results: Of the 60 patients, 30(50%) were in group A; 22(73.3%) males and 8(26.7%) females with mean age 56.63±10.92 years. There were 30(50%) patients in control group B; 24(80%) males and 6(20%) females with mean age 54.8±6.18 (p>0.05). Group A showed significant changes compared to group B in the levels of interleukin-6, serum ferritin, D-dimer, procalcitonin, lymphocytes count and oxygen saturation (p<0.05). Mortality rate was not significantly different between the groups (p>0.05).

Conclusions: Majority of the acute phase inflammatory markers were reduced significantly by treatment with tocilizumab.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以伊拉克患者为样本，研究托珠单抗对伴有细胞因子风暴综合征的严重 COVID-19 患者预后的影响。

目的确定妥昔单抗是否能改善严重冠状病毒病-2019细胞因子风暴综合征住院患者的预后：这项病例对照研究于2020年9月至2021年3月在巴格达的Al-Yarmouk教学医院和伊拉克Thi Qar的Al Shatra综合医院进行，研究对象包括严重获得性呼吸综合征-冠状病毒-2肺炎患者，这些患者不适合机械通气，A组患者接受了单剂量静脉输注8mg/kg的托珠单抗。数据使用 SPSS 26 进行分析：在 60 名患者中，A 组有 30 人（50%），其中男性 22 人（73.3%），女性 8 人（26.7%），平均年龄为（56.63±10.92）岁。对照组 B 有 30 名患者（50%），其中男性 24 名（80%），女性 6 名（20%），平均年龄为（54.8±6.18）岁（P>0.05）。与 B 组相比，A 组在白细胞介素-6、血清铁蛋白、D-二聚体、降钙素原、淋巴细胞计数和血氧饱和度水平上有明显变化（P0.05）：结论：使用托西珠单抗治疗后，大多数急性期炎症指标都明显降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the Pakistan Medical Association Medicine-General Medicine

CiteScore

1.10

自引率

11.10%

发文量

983

审稿时长

3-6 weeks

期刊介绍： Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.